Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024
Summary of opinion: Carvykti, 22/02/2024
Summary of opinion: Xromi, 22/02/2024 Positive
Summary of opinion: Cibinqo, 22/02/2024 Positive
Summary of opinion: Reblozyl, 22/02/2024 Positive
New treatment for rare motor neurone disease recommended for approval
First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria
Committee for Medicinal Products for Veterinary Use (CVMP): 16-18 January 2024, European Medicines Agency, Amsterdam, the Netherlands, from 16 January 2024 to 18 January 2024
Non-clinical and clinical evaluation of antiviral medicinal products and monoclonal antibodies for the prevention and treatment of COVID-19 - Scientific guideline
EMEA-001757-PIP02-15-M03